Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928480 | 0.88 | ALDH1A1 (0.63) | ALDH1A1POLBKDM4ESMN1; SMN2TDP1 | |
| SCHEMBL5391758 | 0.88 | ALDH1A1 (0.60) | ALDH1A1POLBKDM4ESMN1; SMN2TDP1 | |
| SCHEMBL18425852 | 0.84 | ALDH1A1 (0.67) | ALDH1A1POLBKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL4634108 | 0.81 | ENPP2 (0.44) | ALDH1A1POLBKDM4ESMN1; SMN2TDP1 | |
| SCHEMBL5383038 | 0.80 | ALDH1A1 (0.45) | ALDH1A1POLBKDM4ESMN1; SMN2TDP1 | |
| SCHEMBL4027368 | 0.80 | SMN1; SMN2 (0.46) | ALDH1A1KDM4ESMN1; SMN2TDP1KMT2A | |
| SCHEMBL4025535 | 0.79 | HPGD (0.52) | ALDH1A1SMN1; SMN2TDP1L3MBTL1ENPP2 | |
| SCHEMBL5059357 | 0.79 | KDM4E (0.66) | ALDH1A1POLBKDM4ESMN1; SMN2ENPP2 | |
| SCHEMBL5402231 | 0.76 | ALDH1A1 (0.54) | ALDH1A1POLBSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL5258701 | 0.76 | MCHR1 (0.49) | ALDH1A1SMN1; SMN2TDP1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | disclosed |
| EP-1497265-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003089409-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | HTR7, HTR2C, HTR3C | ALDH1A1 1439/4885POLB 4542/4885KDM4E 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.